Patent
The present invention to the identification of a novel isolated bacterial strain, the Limosilactobacillus reuteri strain which is characterized by a naturally occurring overproduction of riboflavin (vitamin B2) compared to other known strains of lactobacilli. Said strain of the Limosilactobacillus species is deposited under accession number LMG P-32020. In a further aspect, also the uses of said L. reuteri strain are disclosed herein. In particular, the use of said strain in food and feed industry, human and veterinary health, large-scale vitamin production, cosmetics and consumer care products is disclosed.
1 . A method of supplementing a subject experiencing riboflavin deficiency, the method comprising administering a probiotic or synbiotic composition to the subject, the probiotic or synbiotic composition comprising an isolated bacterial strain of Lactobacillus reuteri , the strain deposited under accession number LMG P-32020.
2 . The method according to claim 1 , wherein the probiotic or synbiotic composition further comprises one or more additional strains of probiotic bacteria.
3 . The method according to claim 2 , wherein the one or more additional strains of probiotic bacteria comprises Streptococcus thermophilus.
4 . The method according to claim 1 , wherein the probiotic or synbiotic composition further comprises one or more food matrices selected from the group consisting of coconut milk, soy milk, cow's milk, and buttermilk.
5 . The method according to claim 4 , wherein the food matrix is coconut milk.
6 . The method according to claim 1 , wherein the probiotic or synbiotic composition further comprises an animal feed.
7 . The method according to claim 1 , wherein the probiotic or synbiotic composition further comprises a food coloring.
8 . The method according to claim 7 , wherein the food coloring is E101.
9 . The method according to claim 1 , wherein the subject experiencing riboflavin deficiency is suffering from a disease selected from the group consisting of diseases of the nervous system, skin diseases, respiratory diseases, diseases associated with reduced levels of red blood cells, eye diseases, diseases associated with disturbed metabolism of iron, diseases associated with oxidative stress, urogenital diseases or infections, gastrointestinal diseases, general fatigue or weakness, metabolic diseases, immune diseases, headache or migraine, cancer, viral, bacterial, and fungal infections.
10 . The method according to claim 1 , wherein the subject experiencing riboflavin deficiency is a pregnant or lactating human.
11 . The method according to claim 1 , wherein the subject experiencing riboflavin deficiency is experiencing general fatigue or weakness.
12 . The method according to claim 1 , wherein the subject experiencing riboflavin deficiency is experiencing one or more symptoms selected from the group consisting of skin damage, sore throat, edema of oral and mucous membranes, cheilosis, and glossitis.
13 . The method according to claim 1 , wherein the subject experiencing riboflavin deficiency is a non-human mammal.
14 . The method according to claim 13 , wherein the non-human mammal is selected from the group consisting of pigs, sheep, goats, cows, horses, chickens, geese, turkeys, rabbits, cats, and dogs.
15 . The method according to claim 1 , wherein the Lactobacillus reuteri produces riboflavin in the probiotic composition.
16 . The method according to claim 15 , wherein the probiotic composition is a solution, suspension, liquid, or paste, and the riboflavin produced by the Lactobacillus reuteri is present in a concentration of from about 18 μg/ml to about 40 μg/mL.